Abstract CT137: Biomarkers of response to leukemia stem cell targeted therapy with low dose daunorubicin in relapsed/refractory acute leukemia

Patients with acute leukemia harbor chemotherapy-resistant leukemia stem cells (LSC) which ultimately lead to disease relapse in many patients. Clinical trial design of LSC targeted therapy is a challenge. The majority of leukemia cells are differentiated leukemia cells, with LSC comprising

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2018-07, Vol.78 (13_Supplement), p.CT137-CT137
Main Authors: Lin, Tara L., Perry, John M., He, Xi, Reed, Gregory, Zhang, Na, Weir, Scott, McGuirk, Joseph P., Li, Linheng
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with acute leukemia harbor chemotherapy-resistant leukemia stem cells (LSC) which ultimately lead to disease relapse in many patients. Clinical trial design of LSC targeted therapy is a challenge. The majority of leukemia cells are differentiated leukemia cells, with LSC comprising
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2018-CT137